N-Zyme Biomedical

N-Zyme Biomedical

HealthNewark, United States

N-Zyme Biomedical is focused on developing novel therapies for reflux disease, specifically through its pepsin inhibitor platform. The company aims to address significant unmet medical needs in conditions like laryngopharyngeal reflux and gastroesophageal reflux disease. This funding round will accelerate their Phase 2 clinical programs and further their innovative approach to treatment.

$4.6M · Series AVisit website ↗

🏆 Featured in Datapile’s Q3 2026 USA Funding Report

Read the Q3 2026 USA report →
Add this badge to your site
Featured in Datapile’s Q3 2026 USA Funding Report
<a href="https://datapile.co/reports/q3-2026-usa-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q3 2026 USA Funding Report</a>

Funding history

  1. $4.6MSeries A2026-07-21
    Source: news.google.com ↗

Founder

Franco Vigile
Franco Vigile
Co-Founder and Chief Executive Officer

More Health companies

Recently funded startups in the same category.

Related on Datapile